[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-embolism-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-embolism-acute":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,41,73,101,130,154,189,215,255,275,294,313,339,366,391],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100639306","rdw-and-rv-pa-coupling-in-acute-pe-100639306",false,"NCT07616557","RDW and RV-PA Coupling in Acute PE","Association Between Admission Red Cell Distribution Width and Right Ventricular-Pulmonary Arterial Coupling in Acute Pulmonary Embolism","Inclusion Criteria:\n\nAge ≥ 18 years. Acute PE confirmed by computed tomography pulmonary angiogram (CTPA) performed within 24 h of presentation.\n\nCBC obtained within 24 h of admission and before any blood transfusion. Transthoracic echocardiography feasible within 24 h of admission. Written informed consent.\n\nExclusion Criteria:\n\n* Active hematologic malignancy or recent chemotherapy with myelosuppressive intent.\n* Red blood cell transfusion within the preceding 90 days.\n* Known hemoglobinopathy (e.g., sickle cell disease, thalassemia major).\n* Chronic dialysis or eGFR \\\u003C 15 mL\u002Fmin\u002F1.73 m².\n* Pre-existing severe pulmonary hypertension (resting mean PAP ≥ 35 mmHg by prior right heart catheterization or echocardiographic PASP ≥ 60 mmHg before this admission), severe left-sided valvular disease, or known severe biventricular dysfunction.\n* Hemodynamic instability requiring vasopressors at the time of echocardiography, as their hemodynamics may distort RV-PA coupling estimates.\n* Inadequate echocardiographic image quality precluding measurement of TAPSE and a quantifiable TR jet for PASP estimation.\n* Inability to provide informed consent.","ALL","18 Years",{"count":19,"type":20},190,"ESTIMATED","OBSERVATIONAL","Prior work linking RDW to echocardiographic findings in PE has largely focused on isolated parameters such as TAPSE or PASP and has rarely incorporated modern measures of RV-PA coupling. Whether admission RDW reflects the integrated RV-PA interaction - and not merely contractility or pressure in isolation - has not been adequately addressed. Establishing this link would support RDW as a simple, universally available marker of RV vulnerability at first presentation, and would lay the groundwork for future prognostic and mechanistic studies.",[24],"Pulmonary Embolism Acute",[26,27,28],"Embolism","RDW","Right Ventricular-Pulmonary Arterial Coupling","NOT_YET_RECRUITING","2026-05-27",{"date":32,"type":33},"2026-06-01","ACTUAL",{"date":35,"type":20},"2026-06-15",{"date":37,"type":20},"2027-12-15",{"name":39,"class":40},"Assiut University","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100640061","phase-4-pre-discharge-influenza-vaccination-in-patients-hospitalized-for-acute-cardiac-conditions-100640061","NCT07617376","Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions","Inclusion Criteria:\n\n* Acute cardiac hospitalization,\n* Planned discharge home within the next 48 hours following completion of in-hospital treatment,\n* No prior influenza vaccination for the current influenza season.\n\nExclusion Criteria:\n\n* History of a severe adverse reaction to influenza vaccination,\n* Allergy to any component of the vaccine to be administered,\n* Discharge to another hospital for continuation of treatment or discharge to a long-term care facility,\n* Antibiotic therapy to be continued after discharge.",{"count":48,"type":20},400,"INTERVENTIONAL",[51],"PHASE4","Patients hospitalized for acute cardiac conditions-including acute myocardial infarction, acute heart failure, pulmonary embolism, arrhythmias, and hypertensive emergencies-represent a heterogeneous population at very high risk of recurrent cardiovascular events. Influenza infection may act as a trigger for adverse cardiovascular events. Given the persistently low influenza vaccination uptake despite evidence-based benefits observed in vulnerable populations, including patients with cardiac conditions, new strategies to improve vaccination coverage are being explored. Recently, increasing attention has been directed toward an approach already used in fields such as neonatology, where vaccinations are administered prior to hospital discharge.\n\nIn this investigator-initiated, single-center, randomized, open-label interventional study, we will evaluate whether influenza vaccination administered within 24 hours before hospital discharge in patients hospitalized for acute cardiac conditions is safe and effective in reducing subsequent infections, cardiovascular events, and mortality during the 6 months following hospitalization.",[54,55,56,24,57,58],"Myocardial Infarction","Decompensated Chronic Heart Failure","Acute Heart Failure (AHF)","Hypertension Emergency","Arrhythmias",[60,61,62],"influenza vaccination","acute cardiac emergencies","pre-discharg vaccination","RECRUITING","2026-05-20",{"date":32,"type":33},{"date":67,"type":33},"2025-11-12",{"date":69,"type":20},"2027-07-01",{"name":71,"class":40},"Wroclaw Medical University",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":49,"phases":83,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100614488","acute-pulmonary-embolism-treatment-with-the-alphavac-multipurpose-mechanical-aspiration-system-and-the-alphareturn-blood-management-system-evaluation-of-safety-and-effectiveness-100614488","NCT07280247","Acute Pulmonary Embolism Treatment With the AlphaVac Multipurpose Mechanical Aspiration System and the AlphaReturn Blood Management System: Evaluation of Safety and Effectiveness","Acute Pulmonary Embolism Treatment With the AlphaVac Multipurpose Mechanical Aspiration System and the AlphaReturn Blood Management System: Evaluation of Safety and Effectiveness (APEX-Return)","APEX-Return","Inclusion Criteria:\n\nA potential subject will be included in the study if he\u002Fshe meets all the following inclusion criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Subject is 18 years of age and older.\n3. Subject presents clinical signs and symptoms consistent with acute intermediate-risk pulmonary embolism for less than or equal to 14 days.\n4. Subject has a diagnosis of pulmonary embolism detected from computed tomography angiography (CTA).\n5. Subject has a RV\u002FLV ratio of 0.9 or higher.\n6. Subject has a systolic blood pressure (SBP) of 90mmHg or higher.\n7. Subject has a heart rate of 130 beats per minute (BPM) or less prior to the procedure.\n8. Subject is deemed medically eligible for interventional procedure(s) per institutional guidelines and\u002For clinical judgment.\n\nExclusion Criteria:\n\nA potential subject will be excluded from the study if he\u002Fshe meets any of the following exclusion criteria:\n\n1. Subjects who are or may be pregnant as determined by a positive pregnancy test or who are breastfeeding.\n2. Subjects who have any contraindication to systemic or therapeutic doses of heparin or anticoagulants.\n3. Subjects who have used thrombolytics in the 30 days prior to the baseline CTA.\n4. Subjects who have pulmonary hypertension with peak pulmonary artery pressure (PAP) \\> 70 mmHg.\n5. Subjects who have FiO2 requirement \\> 44% or \\> 6 LPM to keep oxygen saturations \\> 90%.\n6. Subjects with hematocrit \\\u003C 28% within 6 hours of index procedure.\n7. Subjects with platelets count \\\u003C 100,000\u002FμL.\n8. Subjects with serum creatinine \\> 1.8 mg\u002FdL.\n9. Subjects with International Normalized Ratio (INR) \\> 3.\n10. Subjects who have undergone a major trauma within the past 14 days of the index procedure and have Injury Severity Score (ISS) \\> 15.\n11. Subjects with the presence of cancer requiring active chemotherapy.\n12. Subjects with known bleeding diathesis or coagulation disorder.\n13. Subjects who have had a cardiovascular or pulmonary surgery within the past 7 days of index procedure.\n14. Subjects with a history of severe or chronic pulmonary hypertension, uncompensated heart failure, chest irradiation, underlying lung disease that is oxygen dependent, heparin-induced thrombocytopenia (HIT) and\u002For chronic left heart disease with left ventricular ejection fraction ≤ 30%.\n15. Subjects with known anaphylactic reaction to radiographic contrast agents that cannot be pretreated.\n16. Subject requires vasopressor after fluids to keep pressure ≥ 90mmHg.\n17. Subjects with left bundle branch block.\n18. Subjects who have intracardiac lead in the right ventricle or atrium.\n19. Evidence such as imaging or other that suggest the subject is not appropriate for this procedure.\n20. Subjects that have life expectancy \\\u003C 90 days, in the opinion of the investigator at the time of enrollment.\n21. Subjects dependent on extracorporeal life support such as extracorporeal membrane oxygenation (ECMO).\n22. Participation in another investigational study.",{"count":82,"type":20},39,[84],"NA","The investigation is intended to evaluate the safety and effectiveness of the AlphaReturn Blood Management System when used in conjunction with the cleared AlphaVac MMA F1885 System for the treatment of acute pulmonary embolism.",[24],[88,89],"pulmonary embolism","alphareturn","2026-05-07",{"date":92,"type":33},"2026-05-11",{"date":94,"type":33},"2026-03-30",{"date":96,"type":20},"2026-12",{"name":98,"class":99},"Angiodynamics, Inc.","INDUSTRY",6,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":72},"100632119","hemodynamic-and-respiratory-instability-during-percutaneous-pulmonary-thrombectomy-100632119","NCT07509541","Hemodynamic and Respiratory Instability During Percutaneous Pulmonary Thrombectomy","Hemodynamic and Respiratory Instability During Percutaneous Pulmonary Thrombectomy in Pulmonary Embolism: Mechanisms, Timing, and Clinical Impact","INSTAB-PE","Inclusion Criteria:\n\n* Patients (aged ≥18 years) with high-risk or intermediate-high-risk pulmonary embolism\n* Patients undergoing percutaneous pulmonary thrombectomy as part of routine clinical care\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Low-risk pulmonary embolism\n* Patients not undergoing percutaneous pulmonary thrombectomy\n* Patients presenting with refractory shock upon arrival to the interventional suite",{"count":110,"type":20},100,"Pulmonary embolism (PE) is a potentially life-threatening condition caused by the obstruction of pulmonary arteries by thrombi. Patients with high-risk or intermediate-high-risk PE may require immediate reperfusion therapies, including percutaneous pulmonary thrombectomy. However, this procedure can be associated with significant hemodynamic and respiratory instability, potentially leading to shock, cardiac arrest, or the need for advanced support such as mechanical ventilation or extracorporeal membrane oxygenation (ECMO).\n\nThe mechanisms, timing, and causes of intraprocedural hemodynamic and respiratory deterioration during pulmonary thrombectomy are not well established. Factors such as catheter manipulation within the pulmonary arteries, increased pulmonary pressures, and the effects of anesthesia and mechanical ventilation may contribute to clinical instability. In addition, biomarkers such as NT-proBNP may reflect right ventricular strain and could help predict the risk of instability during the procedure.\n\nThe aim of this prospective observational study is to determine the incidence, causes, and timing of hemodynamic and\u002For respiratory instability during percutaneous pulmonary thrombectomy in patients with high-risk or intermediate-high-risk PE. The study will also compare the occurrence of instability between different thrombectomy devices (FlowTriever® and Indigo® systems) and evaluate the prognostic role of baseline NT-proBNP levels. Secondary objectives include the assessment of in-hospital and 30-day mortality and their underlying causes.\n\nThis study will include adult patients undergoing percutaneous pulmonary thrombectomy as part of routine clinical care. The results of this study may help improve risk stratification, guide procedural planning, and optimize the management of patients undergoing pulmonary thrombectomy, ultimately aiming to reduce morbidity and mortality.",[24],[114,115,116,117,118,119,120],"Pulmonary Embolism","Percutaneous Pulmonary Thrombectomy","Catheter-Directed Thrombectomy","Hemodynamic Instability","Respiratory Instability","Shock","NT-proBNP","2026-04-28",{"date":123,"type":33},"2026-05-04",{"date":125,"type":20},"2026-04-10",{"date":127,"type":20},"2030-05-10",{"name":129,"class":40},"Hospital Universitari Vall d'Hebron Research Institute",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":136,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":49,"phases":139,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":72},"100633471","role-of-n-on-contrast-chest-ct-ncct-based-ct-v-q-in-patients-with-acute-pulmonary-embolism-ape-100633471","NCT07527117","Role of n On-contrast Chest CT (NCCT) Based CT V: Q in Patients With Acute Pulmonary Embolism (aPE)","Inclusion Criteria:\n\n1. Patients undergoing CTPA for suspected aPE\n2. Patients who provide written informed consent to participate\n3. Adults patients \\>\u002F= 21 years of age\n4. Mini Mental State Exam (MMSE) score of 18 or more.\n\nExclusion Criteria:\n\n1. Patients who decline informed consent\n2. Patients with known chronic PE\n3. Patients with known interstitial lung diseases\n4. Patients who cannot raise their arms above their shoulders (arms can cause serious artifacts)\n5. Women of child-bearing potential (\\\u003C 55 years) who test positive for pregnancy test\n6. Patients \\\u003C 21 years of age (to avoid research radiation dose in young patients)\n7. Patients with any EMR documented cognitive impairment or diseases such as dementia, recent head injury, psychiatric disorders, or other neurological diseases that impair decision-making.\n8. Pregnant subjects\n9. Women of child-bearing potential (21-55 years) who refuse to take a urine pregnancy test prior to their CT examination\n10. Mini Mental State Exam (MMSE) score of less than 18.","21 Years",{"count":138,"type":20},750,[84],"We are doing the research to see if a CT scan without the dye can help find pulmonary emboli. If you agree to join the study, you will be asked to sign this consent form before we do any research procedures. If you join the research, we will ask you to blow into a small device known as a spirometer to train you to hold your breath after you inhale and exhale. Spirometer is a small handheld device to find out how well your lungs work when you inhale and exhale. For this research, we will obtain two extra sets of CT images at very low levels of radiation dose. The two extra sets of images will take less than 1 minute. Your total participation time is about 5 minutes. We will also review your medical record for up to 30 to 90 days after your CT scan.\n\nThe main risks of being in the study are exposure to ionizing radiation which may have health risks, and minor inconvenience from the spirometer test.\n\nYou will not benefit from taking part in this research study. If you take part in this study, your participation may help people in the future. If you decide not to be in the study, you will still have the standard-of-care chest CT with the dye ordered by your doctor. You will not be paid for taking part in this research study.",[142,24],"Pulmonary Embolism (Diagnosis)",[144],"CT ventilation perfusion pulmonary embolism CT pulmonary angiogram","2026-04-07",{"date":147,"type":33},"2026-04-14",{"date":149,"type":20},"2026-07-01",{"date":151,"type":20},"2028-12-31",{"name":153,"class":40},"Massachusetts General Hospital",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":163,"conditions":164,"keywords":168,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100630701","repeated-examinations-for-typing-pulmonary-embolism-100630701","NCT07491094","Repeated Examinations for Typing Pulmonary Embolism","Repeated Examinations for Typing Pulmonary Embolism (RE-TyPE)","RE-TyPE","Inclusion Criteria:\n\n1. Adult patients (≥ 18 years old) who is diagnosed with, or followed as out-patients for, PE at Sahlgrenska University Hospital\n2. Written informed consent\n\nExclusion Criteria from Cohort A:\n\n1. Low risk, intermediate-low risk or high risk PE\\*\n2. \\>48 hours since arrival to hospital\n3. Expected inability to comply with the protocol (e.g. dementia)\n\nThere are no exclusion criteria from Cohort B. Patients in Cohort B who are not part of Cohort A may be included at diagnosis (day 0) or at follow-up (\\~day 90).\n\n\\*If biomarkers (and\u002For echocardiography) are not available in hemodynamically stable patients, RV\u002FLV-ratio \\>1 will be considered as preliminary intermediate-high risk. If biomarkers later fall out negative, the patient will be considered as intermediate-low risk and will be moved to Cohort B",{"count":48,"type":20},"PURPOSE\n\nThe two related purposes of the RE-TyPE study are:\n\n1. To improve understanding of the early clinical course of intermediate-high risk pulmonary embolism and its association with outcome and\n2. To establish a platform for longitudinal follow-up for all pulmonary embolism at Sahlgrenska University Hospital\n\nHYPOTHESES\n\n1. The dynamic pattern of change, evaluated thorough repeated measures of biomarkers, electrocardiography and echocardiography during the first 48 hours after pulmonary embolism, better predicts outcome than static measurements currently used to predict outcome\n2. Establishment of a platform for longitudinal follow-up will improve quality of care and outcome for patients with pulmonary embolism at Sahlgrenska University Hospital",[142,24,165,166,167],"Pulmonary Embolism With Acute Cor Pulmonale","Pulmonary Embolism With Right Ventricle Enlargement","Pulmonary Embolism (PE)",[169,170,171,172,173,174,175,176,177,178],"Echocardiography","Point Of Care UltraSound (POCUS)","Electrocardiography (ECG)","Biomarkers\u002FBlood","Troponin I","NT-pro-BNP","Lactate","Prediction model","Clinical deterioration","Death","2026-04-02",{"date":181,"type":33},"2026-04-06",{"date":183,"type":33},"2026-04-01",{"date":185,"type":20},"2032-01-01",{"name":187,"class":40},"Sahlgrenska University Hospital",3,{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":214},"100626520","optimal-time-for-reperfusion-in-acute-pulmonary-embolism-100626520","NCT07436702","Optimal Time for Reperfusion in Acute Pulmonary Embolism","OPTIRAPE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients with a diagnosis of intermediate-high or high pulmonary embolism confirmed by computed tomography pulmonary angiography (CTPA), pulmonary angiography, or echocardiography (evidence of a floating thrombus in the right atrium or right ventricle, or proximal visualization of thrombus in the pulmonary artery).\n* Classified as high-risk or intermediate-high-risk according to the 2019 European Society of Cardiology guidelines.\n* Provision of informed consent for the processing of personal data.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Patients in whom a diagnosis of acute high-risk or intermediate-high-risk pulmonary embolism has been excluded.\n* Inability to provide informed consent.",{"count":197,"type":20},500,"Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality worldwide. Current guidelines recommend early reperfusion for high-risk and intermediate-high-risk PE, yet systemic thrombolysis and percutaneous therapies are frequently underutilized, and no specific timing for reperfusion is defined, unlike in acute myocardial infarction or ischemic stroke. As most PE-related in-hospital deaths occur within the first hours and thrombus composition changes over time, defining an optimal reperfusion time window may improve survival and prevent hemodynamic deterioration. We therefore propose a national, multicenter, prospective observational study to evaluate the prognostic impact of reperfusion timing, using systemic thrombolysis or catheter-directed therapies, on in-hospital mortality and haemorrhagic or cardiovascular complications.",[142,24],[201,202,203,204],"Fibrinolysis","Anticoagulation","Catheter-directed treatments","Time of Reperfusion","2026-03-01",{"date":207,"type":33},"2026-03-03",{"date":209,"type":33},"2025-11-25",{"date":211,"type":20},"2026-10-30",{"name":213,"class":40},"Azienda ULSS 8 Berica",7,{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":49,"phases":224,"briefSummary":225,"conditions":226,"keywords":233,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":72},"100528865","interest-of-the-chair-lift-test-in-the-prognostic-evaluation-of-pulmonary-embolism-a-single-center-open-prospective-study-100528865","NCT06166329","Interest of the Chair Lift Test in the Prognostic Evaluation of Pulmonary Embolism: a Single-center Open Prospective Study","SIT-EP","Inclusion Criteria:\n\n* Diagnosis of pulmonary embolism according to clinical algorithm, confirmed by thoracic angioscan or ventilation perfusion (V\u002FP) scan,\n* Non-serious pulmonary embolism, not requiring intensive care (thrombectomy or fibrinolysis not considered).\n* sPESI score ≥ 1 \\[or = 0 with elevated troponin or presence of markers of VD dysfunction, or = 0 with need for hospitalization due to comorbidities unrelated to PE (social isolation, comprehension disorders, intercurrent infection, chronic renal failure, advanced cancer...)\n* Patients with no contraindications to chair lift testing (no O2 at the time of testing).\n* Effective anticoagulation for at least 1 hour.\n\nExclusion Criteria:\n\n* sPESI score = 0 with outpatient referral.\n* Diagnostic confirmation of Pulmonia Embolism by thoracic angioscan or scintigraphy more than 24h after suspicion of diagnosis.\n* Hospitalization \\> 24h after introduction of anticoagulation, with subsequent confirmation by scintigraphy.\n* Any sign of serious Pulmonia Embolism, requiring hospitalization in an intensive care unit.\n* Asymptomatic Pulmonia Embolism discovered by chance",{"count":223,"type":20},180,[84],"The objective of the study is to evaluate the prognostic performance of the chair lift test in the initial assessment of the severity of non-severe pulmonary embolism in hospitalized patients, in comparison with the current pulmonary embolism risk stratification score using the sPESI score refined by the use of cardiac biomarkers and right ventricular dysfunction",[227,114,228,24,229,230,231,232],"Non-severe Pulmonary Embolism","Non-high-risk Pulmonary Embolism","Prognostic Stratification","Risk Assessment in Pulmonary Embolism","Functional Exercise Testing","Early Prognostic Evaluation",[114,234,235,236,237,238,239,240,241,242,120,243,244,245],"Prognostic Evaluation","Risk Stratification","sPESI Score","Chair Stand Test","One-Minute Sit-to-Stand Test","Functional Capacity","Right Ventricular Dysfunction","Cardiac Biomarkers","Troponin","Early Mortality","Ambulatory Management","Hospitalized Patients","2026-02-13",{"date":248,"type":33},"2026-02-17",{"date":250,"type":33},"2024-02-09",{"date":252,"type":20},"2027-02",{"name":254,"class":40},"University Hospital, Rouen",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":49,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":272,"locationsCount":274},"100567770","safety-and-effectiveness-of-the-akura-thrombectomy-system-for-use-in-the-removal-of-emboli-from-the-pulmonary-arteries-in-treating-acute-pulmonary-embolism-pe-100567770","NCT06672510","Safety and Effectiveness of the Akura Thrombectomy System for Use in the Removal of Emboli From the Pulmonary Arteries in Treating Acute Pulmonary Embolism (PE)","Inclusion Criteria:\n\n* The patient is 18 years of age or older and deemed medically eligible for interventional procedure, per institutional guidelines and clinical judgement\n* Clinical signs, symptoms and presentation consistent with acute PE\n* PE symptom duration ≤ 14 days\n* CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery)\n* CTA evidence of RV\u002FLV ratio of ≥ 0.9 (NOTE: Enrollment qualification assessment is based on the Investigator's interpretation of RV\u002FLV ratio at baseline)\n* Systolic BP ≥ 90 mmHg (initial SBP may be \\\u003C 90 mmHg but ≥ 80 mmHg if the pressure recovers with volume resuscitation)\n* Stable HR \\\u003C 130 BPM prior to the procedure\n\nExclusion Criteria:\n\n* Prior PE \\\u003C180 days from index procedure\n* Thrombolytic use within 30 days prior to baseline CTA\n* Pulmonary hypertension with peak pulmonary arterial pressure (PAP) \\> 70 mmHg by right heart catheterization\n* Vasopressor requirement after fluids to keep pressure at ≥ 90 mmHg\n* FiO2 requirement \\> 40% or \\> 6 LPM (to keep oxygen saturation \\> 90%)\n* Hematocrit \\\u003C 28% (Note: hematocrit required within 6 hrs. of index procedure)\n* Platelets \\\u003C 100,000\u002FμL\n* eGFR \\\u003C30 ml\u002Fmin per 1.73 m2\n* International normalized ratio (INR) \\> 3\n* Major trauma injury severity score (ISS) \\> 15\n* Presence of intracardiac lead in right ventricle or atrium placed ≤ 6 months of enrollment\n* Cardiovascular or pulmonary surgery within the last 7 days\n* Actively progressing cancer treated by chemotherapeutics\n* Known bleeding diathesis or coagulation disorder\n* Left bundle branch block\n* History of severe or chronic pulmonary arterial hypertension\n* History of chronic left heart disease with left ventricular ejection fraction ≤ 30%\n* History of uncompensated heart failure.\n* History of underlying lung disease that is oxygen dependent\n* History of chest irradiation\n* History of heparin-induced thrombocytopenia (HIT)\n* Contraindication to systemic or therapeutic doses of anticoagulants\n* Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated\n* Known residual iliac deep vein thrombosis (DVT), inferior vena cava (IVC) clot or clot in transit (right atrium and\u002For right ventricle)\n* CTA imaging or other evidence that suggest, in the opinion of the investigator, the Subject is not appropriate for mechanical thrombectomy intervention (e.g. inability to navigate to target location, predominantly chronic clot or non-clot embolus)\n* Life expectancy \\\u003C 90 days, as determined by investigator (e.g., stage 4 cancer, frailty or severe COVID infections)\n* Female who is pregnant or nursing\n* Current participation in another investigational drug or device treatment study",{"count":262,"type":20},118,[84],"This study is a prospective, single-arm, interventional, multicenter study to evaluate the safety and effectiveness of percutaneous mechanical thrombectomy using the Akura Thrombectomy System in subjects with acute pulmonary embolism (PE).",[24],"2025-12-11",{"date":268,"type":33},"2025-12-17",{"date":270,"type":33},"2025-01-01",{"date":96,"type":20},{"name":273,"class":99},"Akura Medical",12,{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":49,"phases":283,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":72},"100543980","safety-and-effectiveness-of-the-akura-thrombectomy-system-in-the-treatment-of-acute-pulmonary-embolism-100543980","NCT06362928","Safety and Effectiveness of the Akura Thrombectomy System in the Treatment of Acute Pulmonary Embolism","Inclusion Criteria:\n\n1. Patient is \\> 18 and \\\u003C 90 years old\n2. Clinical signs and symptoms consistent with acute PE\n3. PE symptom duration ≤ 14 days\n4. CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery as determined by the investigator)\n5. CTA evidence of RV\u002FLV ratio \\> 0.9 note: based on Investigator's interpretation of RV\u002FLV ratio at baseline;\n6. Systolic BP ≥ 90 mmHg note: initial SBP may be \\\u003C 90 mmHg but ≥ 80 mmHg if the pressure recovers with volume resuscitation\n7. Stable heart rate (HR) \\\u003C 130 BPM prior to procedure\n8. Patient is deemed medically eligible for interventional procedure(s), per investigator guidelines and clinical judgment.\n9. Subject or legally authorized representative (LAR) is willing and able to provide written informed consent prior to receiving any non-standard of care protocol specific procedures\n\nExclusion Criteria:\n\n1. Prior PE \\\u003C 180 days from index procedure\n2. Thrombolytic use \\\u003C 48 hours prior to baseline CTA\n3. Pulmonary hypertension with peak pulmonary artery systolic pressure (PASP) \\>70 mmHg by right heart catheterization\n4. Vasopressor requirement after fluids to keep pressure at ≥90 mmHg\n5. FiO2 requirement \\>40% or \\>6 LPM to keep oxygen saturation \\>90%\n6. Hematocrit \\\u003C28% (Note: hematocrit required within 6 hrs. of index procedure)\n7. Platelets count \\\u003C100,000\u002FµL\n8. eGFR \\\u003C30 ml\u002Fmin per 1.73 m2\n9. International normalized ratio (INR) \\>3\n10. Major trauma injury severity score (ISS) \\> 15\n11. Presence of intracardiac lead in right ventricle or atrium placed within 6 months prior to screening assessment\n12. Cardiovascular or pulmonary surgery within 7 days of index procedure\n13. Actively progressing cancer treated by chemotherapeutics\n14. Known bleeding diathesis or coagulation disorder\n15. Left bundle branch block\n16. History of severe or chronic pulmonary arterial hypertension\n17. History of chronic left heart disease with left ventricular ejection fraction ≤ 30%\n18. History of decompensated heart failure\n19. History of underlying lung disease that is oxygen dependent\n20. History of chest irradiation\n21. History of heparin-induced thrombocytopenia (HIT)\n22. Contraindication to systemic or therapeutic doses of anticoagulants\n23. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated\n24. Known residual iliac deep vein thrombosis (DVT), inferior vena cava (IVC) clot or clot in transit (right atrium and\u002For right ventricle).\n25. CTA imaging or other evidence that suggest, in the opinion of the investigator, the Subject is not appropriate for aspiration thrombectomy intervention (e.g., inability to navigate to target location, predominantly chronic clot or non-clot embolus)\n26. Life expectancy \\\u003C90 days, as determined by investigator\n27. Female who is pregnant or nursing\n28. Current participation in another investigational drug or device treatment study Note: observational or registry studies may be permitted with Sponsor approval","90 Years",{"count":5,"type":20},[84],"This study is a prospective, single-arm, non-randomized, interventional, multicenter feasibility study to evaluate the safety and effectiveness of percutaneous mechanical thrombectomy using the Akura Thrombectomy System in subjects with acute pulmonary embolism (PE).",[24],"2025-07-24",{"date":288,"type":33},"2025-07-28",{"date":290,"type":33},"2025-02-15",{"date":292,"type":20},"2026-02",{"name":273,"class":99},{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":281,"enrollmentInfo":301,"targetDuration":4,"studyType":49,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":312},"100527790","safety-and-effectiveness-of-the-atc-system-in-the-treatment-of-acute-pe-100527790","NCT06152341","Safety and Effectiveness of the ATC System in the Treatment of Acute PE","Safety and Effectiveness of the ATC System in the Treatment of Acute Pulmonary Embolism","Inclusion Criteria:\n\n1. Patient is ≥ 18 and ≤ 90 years old\n2. Clinical signs and symptoms consistent with acute PE for \\\u003C 14 days\n3. CTA evidence of proximal PE\n4. RV\u002FLV ratio \\> 0.9\n5. Systolic BP ≥90 mmHg without the need for vasopressors\n6. Stable heart rate (HR) \\\u003C 130 BPM prior to procedure\n7. Patient is deemed medically eligible for interventional procedure(s), per investigator guidelines and clinical judgment\n8. Subject or legally authorized representative (LAR) is willing and able to provide written informed consent prior to receiving any non-standard of care protocol specific procedures\n\nExclusion Criteria:\n\n1. Prior PE \\\u003C 180 days from index procedure\n2. Thrombolytic use \\\u003C 30 days prior to baseline CTA\n3. Pulmonary hypertension with peak pulmonary artery systolic pressure (PASP) \\>70 mmHg by right heart catheterization\n4. FiO2 requirement \\>40% or \\>6 LPM to keep oxygen saturation \\>90%\n5. Hematocrit \\\u003C28%\n6. Platelets count \\\u003C100,000\u002FµL\n7. Serum creatinine \\>1.8 mg\u002FdL\n8. International normalized ratio (INR) \\>3\n9. Major trauma injury severity score (ISS) \\>15 prior to screening assessment\n10. Presence of intracardiac lead in right ventricle or atrium placed within 6 months prior to screening assessment\n11. Cardiovascular or pulmonary surgery within 7 days of index procedure\n12. Actively progressing cancer treated by chemotherapeutics\n13. Known bleeding diathesis or coagulation disorder\n14. Left bundle branch block\n15. History of severe or chronic pulmonary arterial hypertension\n16. History of chronic left heart disease with left ventricular ejection fraction ≤ 30%\n17. History of decompensated heart failure\n18. History of underlying lung disease that is oxygen dependent\n19. History of chest irradiation\n20. History of heparin-induced thrombocytopenia (HIT)\n21. Contraindication to systemic or therapeutic doses of anticoagulants\n22. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated\n23. Imaging evidence or other evidence that suggest, in the opinion of the investigator, the Subject is not appropriate for aspiration thrombectomy intervention\n24. Life expectancy \\\u003C90 days, as determined by investigator such as stage 4 cancer, frailty or severe COVID infections\n25. Female who is pregnant or nursing\n26. Current participation in another investigational drug or device treatment study.",{"count":302,"type":20},30,[84],"This study is a prospective, single-arm, interventional, multicenter study to evaluate the safety and effectiveness of the ATC System in subjects with acute pulmonary embolism (PE).",[24],{"date":288,"type":33},{"date":308,"type":33},"2024-05-15",{"date":310,"type":20},"2025-09-15",{"name":273,"class":99},4,{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":321,"targetDuration":323,"studyType":21,"phases":4,"briefSummary":324,"conditions":325,"keywords":328,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":72},"100595237","cohort-study-on-treatment-comes-of-catheter-based-therapy-in-patients-with-acute-pulmonary-embolism-in-hong-kong-100595237","NCT07029841","Cohort Study on Treatment Comes of Catheter-based Therapy in Patients With Acute Pulmonary Embolism in Hong Kong","Cohort Study on Treatment Comes of Catheter-based Therapy in Patients With Acute Pulmonary Embolism in Hong Kong - the HONG KONG PECT Registry","HK-PECT","Inclusion Criteria:\n\n* Patients who is admitted with a diagnosis of acute pulmonary embolism\n* Patient who receives any types of catheter-based therapy for acute pulmonary embolism.\n\nExclusion Criteria:\n\n* nil. This is a all-comer registry.",{"count":322,"type":20},1000,"90 Days","This retrospective cohort study (Hong Kong PECT Registry) compares treatment outcomes between different percutaneous catheter-based therapies in patients with acute pulmonary embolism (PE). PE is a critical condition with potential for rapid deterioration and mortality before treatment. While availability of catheter-based therapy contributed to the declining mortality rates of PE, selecting the appropriate intervention remains key. There are primarily two modes of therapies available: Catheter-directed thrombolysis and Aspiration thrombectomy (e.g., Penumbra, Flowtriever, AlphaVac) Given limited direct comparisons between these methods, the study will evaluate their efficacy, safety, and clinical outcomes of these treatment strategies in acute PE patients.",[24,326,327],"Pulmonary Embolism Acute Massive","Pulmonary Embolism Subacute Massive",[329],"PE, CDT, LBAT, UACDT","2025-06-17",{"date":332,"type":33},"2025-06-19",{"date":334,"type":33},"2022-06-01",{"date":336,"type":20},"2032-12-30",{"name":338,"class":40},"Chinese University of Hong Kong",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":346,"targetDuration":348,"studyType":21,"phases":4,"briefSummary":349,"conditions":350,"keywords":353,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":72},"100542868","registry-of-catheter-intervention-in-pulmonary-embolism-100542868","NCT06348459","Registry of Catheter Intervention in Pulmonary Embolism","RiTEP","Inclusion Criteria:\n\n* adult patients (aged 18 years old or older)\n* confirmed diagnosis of acute PE (on computed tomography or echocardiogram plus pulmonary angiography)\n* high-risk PE or intermediate-high risk according to ESC risk stratification in the 2019 guidelines (briefly, elevated cardiac biomarkers \\[troponin or N-terminal pro-B-type natriuretic peptide\\], and right ventricle to left ventricle ratio \\> 0.9 \\[on computed tomography or echocardiogram\\], and PE severity index III to IV or simplified PE severity index=1\n* eligibility for catheter-directed intervention\n\nExclusion Criteria:\n\n* unconfirmed diagnosis of PE\n* undefined risk stratification, and\n* PE with uncertain chronology or beyond seven days of symptom initiation.",{"count":347,"type":20},300,"2 Years","Multicenter longitudinal observational ambispective (retrospective cases from 2014 and prospective from 2018 onwards) cohort study. The registry recruits a series of consecutive patients admitted for moderate-high risk or high-risk pulmonary embolism (according to 2019 European Society of Cardiology guidelines) treated invasively. This study aims to describe the acute management of the safety and effectiveness of different percutaneous interventions for acute pulmonary embolism.",[114,326,24,351,352],"Pulmonary Embolism and Thrombosis","Pulmonary Thromboembolisms",[354,355,356],"Aspiration Thrombectomy","Percutaneous Aspiration Thrombectomy","Local Thrombolysis","2025-04-23",{"date":359,"type":33},"2025-04-25",{"date":361,"type":33},"2018-09-18",{"date":363,"type":20},"2030-12-31",{"name":365,"class":40},"Hospital San Carlos, Madrid",{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":49,"phases":375,"briefSummary":376,"conditions":377,"keywords":378,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":72},"100580171","thrombectomy-in-high-risk-pulmonary-embolism---device-versus-thrombolysis-netherlands-torpedo-nl-100580171","NCT06833827","'Thrombectomy in High-Risk Pulmonary Embolism - Device Versus Thrombolysis Netherlands': TORPEDO-NL","TORPEDO-NL","Inclusion Criteria:\n\n1. Adult patients with confirmed acute PE, i.e. contrast filling defect in a lobar or more proximal pulmonary artery on computed tomography pulmonary angiography (CTPA), and\u002For obstructive shock with echocardiographic confirmed dilatation of the right ventricle and a congested vena cava inferior, both with\u002Fwithout echocardiographic signs of clot in transit or deep vein thrombosis of the leg.\n2. High risk for mortality, i.e.\n\n   1. post cardiac arrest (after temporary need for cardiopulmonary resuscitation), OR\n   2. obstructive shock (systolic blood pressure \\\u003C90 mmHg and signs of end-organ hypoperfusion (e.g. elevated lactate levels \\>2 mmol\u002Fl) or the need for vasopressors (adrenalin or noradrenalin) to maintain an adequate blood pressure), OR\n   3. persistent hypotension (systolic blood pressure \\\u003C90 mmHg or systolic blood pressure drop ≥40 mmHg for at least 15 minutes) not caused by new onset arrhythmia, hypovolemia, or sepsis, OR\n   4. abnormal RV function on transthoracic echocardiography or CTPA AND elevated cardiac troponin levels AND respiratory failure defined as hypoxemia (SaO2 \\\u003C90%) refractory to O2 supplementation by nasal cannula or Venturi mask, requiring full face mask O2 supplementation (100% FiO2), high-flow nasal O2, or (non-)invasive mechanical ventilation.\n3. CDT available and technically feasible so as to allow for a randomization-to-needle time of 60 minutes or less.\n\nExclusion Criteria:\n\n1. \"Catastrophic PE\", i.e. ongoing cardiac arrest and\u002For need for extracorporeal cardiopulmonary resuscitation (ECPR) and\u002For immediate indication for venoarterial extracorporeal membrane oxygenation (VA-ECMO) as judged by the responsible physician(s)\n2. Glascow Coma Scale \\\u003C8 following resuscitation for cardiac arrest\n3. Alternative diagnosis than acute PE contributing largely to the acute hemodynamic and\u002For respiratory failure, e.g. sepsis, COPD GOLD 3 or 4, or known heart failure with NYHA Functional Classification of 4, as judged by the treating physician.\n4. A known \"do not admit to the ICU\" or \"do not resuscitate\" directive\n5. An absolute contraindication to systemic thrombolysis, i.e.\n\n   * History of hemorrhagic stroke\n   * Ischemic stroke in past 6 months\n   * Central nervous system neoplasm\n   * Major trauma, major surgery or major head injury in past 3 weeks (note: mild external laceration of the head after, e.g. syncope, does not count as major head injury, especially when a CT scan of the head shows no hematoma)\n   * Active bleeding, life-threatening or into a critically organ\u002Farea; OR known severe bleeding diathesis with previous bleeding fulfilling these criteria\n6. Reperfusion therapy (systemic thrombolysis, surgical thrombectomy or CDT\u002Fother catheter directed therapy), or placement of a non-retrieved inferior vena cava filter for acute pulmonary embolism in the past 3 months\n7. Thrombus in transit through a patent foramen ovale.\n8. Known chronic thromboembolic pulmonary hypertension (CTEPH), or strong suspicion of CTEPH based on pre-existing clinical findings and combinations of signs of PE chronicity on echocardiography and\u002For CTPA.\n9. Known hypersensitivity to systemic thrombolysis, heparin, or to any of the excipients\n10. If, in the Investigator's opinion, or after consultation with the local PERT-team or EC-members, the patient is not appropriate for thrombectomy\n11. Chronic use of full-dose oral or parenteral anticoagulation before presentation.\n12. Pregnancy\n13. Current participation in another study that would interfere with participation in this study\n14. Previous enrolment in this study\n15. Refusal of deferred consent by the next of kin or by the patient himself to use the data. Deferred consent will not be asked to relatives of patients who die in scene, but are included in the study.",{"count":374,"type":20},111,[84],"TORPEDO-NL will be an investigator-initiated, academically sponsored, multicentre, open-label, randomized controlled trial (RCT).\n\nPatients with high-risk pulmonary embolism (PE) require immediate reperfusion therapy on top of anticoagulation. The standard reperfusion treatment in these patients is full-dose systemic thrombolysis. This carries a significant risk of major bleeding (10-25%) and intracranial haemorrhage (ICH, 3%). Catheter-directed thrombectomy (CDT) is a promising alternative to systemic thrombolysis with a more direct effect on reducing pulmonary artery clot burden and very likely a better safety profile. Randomized trials evaluating the safety and efficacy of CDT in high-risk patients are currently unavailable. The investigators hypothesize that in high-risk PE patients, CDT is superior to the current standard of systemic thrombolysis in terms of mortality and adverse events, i.e., is associated with a lower composite incidence of all-cause mortality, treatment failure, major bleeding and all-cause stroke. The investigators also hypothesize that CDT will lead to a shorter length of stay (LOS) at the intensive care unit (ICU) and in-hospital, faster recovery, and better long-term quality of life (QoL).\n\nObjective: To determine whether CDT in high-risk PE relative to systemic thrombolysis is:\n\n* more effective and safer in terms of a reduction of the composite endpoint on all-cause mortality and adverse events defined as treatment failure, major bleeding and all-cause stroke at day 30 (primary outcome)\n* leads to a better Desirability of Outcome Ranking (DOOR) at day 7\n* associated with a lower level of oxygen supplementation at 48 hours\n* associated with shorter length of stay (LOS) at the intensive care unit (ICU) and in the hospital\n* associated with better functional recovery as well as better patient-reported outcomes such as QoL at one year\n* cost-effective after a time horizon of one year",[24],[379,380,381],"Acute Pulmonary Embolism","Full dose systemic thrombolysis","Catheter-directed thrombectomy","2025-02-13",{"date":384,"type":33},"2025-02-19",{"date":386,"type":20},"2025-02",{"date":388,"type":20},"2029-01",{"name":390,"class":40},"Leiden University Medical Center",{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":49,"phases":400,"briefSummary":401,"conditions":402,"keywords":403,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":72},"100553512","evaluation-of-the-standard-catheter-directed-thrombolysis-effectiveness-in-intermediate-high-risk-pulmonary-embolism-patients-100553512","NCT06487052","Evaluation of the Standard Catheter-directed Thrombolysis Effectiveness in Intermediate-High-Risk Pulmonary Embolism Patients","Evaluation of the Standard Catheter-directed Thrombolysis (SCDT) Effectiveness in Intermediate-High-Risk Pulmonary Embolism Patients","ESCADlys-PE","Inclusion Criteria:\n\n* Age \\> 18 years\n* Computed tomography angiography (CTA) - verified proximal (pulmonary trunk and\u002For main and\u002For lobar branches of the pulmonary artery) PE and symptom onset \\\u003C 14 days prior\n* Intermediate-high risk PE with a RV dysfunction (RV\u002FLV diameter ratio \\>1 on TTE or CTA) and an elevated biomarker (hs-troponin or NT-proBNP) level\n* Signed informed consent\n\nExclusion Criteria:\n\n* High-risk pulmonary embolism\n* Thrombus in the heart chambers on TTE\n* Absolute contraindications for the use of thrombolytic therapy: history of hemorrhagic stroke or stroke of unknown etiology; ischemic stroke or transient ischemic attack within the last 6 months; extensive bleeding currently or within the previous 6 months, hemorrhagic diathesis; diseases of the central nervous system (including neoplasms, aneurysm, surgery on the brain or spinal cord); intracranial (including subarachnoid) hemorrhage currently or in history, suspicion of hemorrhagic stroke; severe uncontrolled arterial hypertension; major surgery or major trauma within the previous 3 months, recent traumatic brain injury; labor during the previous 10 days; severe liver diseases, including liver failure, cirrhosis, portal hypertension (including esophageal varices) and active hepatitis; bacterial endocarditis, pericarditis; acute pancreatitis; confirmed peptic ulcer of the stomach or duodenum within the last 3 months; arterial aneurysms, congenital anomalies of arteries\u002Fveins;\n* Haemoglobin level \\\u003C 70 g\u002FL, platelet count ≤ 100 x 109\n* Allergic to alteplase or UFH or contrast allergy\n* Pregnant or breastfeeding\n* Clinically significant malignancies",{"count":110,"type":20},[84],"A single-center, open-label, randomized comparative study of two treatment strategies in patients with intermediate-high-risk acute pulmonary embolism (PE). Patients will be randomized in a 1:1 ratio to standard anticoagulant therapy or standard catheter-directed thrombolysis (SСDT) with a low dose of alteplase, followed by evaluation of short- and long-term efficacy and safety in each group",[24],[404,405,406],"acute pulmonary embolism","catheter-directed thrombolysis","anticoagulant therapy","2024-06-27",{"date":409,"type":33},"2024-07-05",{"date":411,"type":33},"2024-01-10",{"date":413,"type":20},"2027-12",{"name":415,"class":40},"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health"]